Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease
Kathryn A Haynes, Diogo Francisco Silva Santos, Sean‐Paul Gerard Williams, Jason T Hart, Alicia M Lehman, Seana E Eckels, Umesh Nepali, Aman Reddy, Toren Finkel, Stacey J Sukoff Rizzo · 2025
Read Cell type specific contributions of mTOR inhibition that drive neuroprotective mechanisms in Alzheimer’s disease by Kathryn A Haynes, Diogo Francisco Silva Santos, Sean‐Paul Gerard Williams, Jason T Hart, Alicia M Lehman, Seana E Eckels, Umesh Nepali, Aman Reddy, Toren Finkel, Stacey J Sukoff Rizzo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710433.txt.
Description
Kathryn Haynes and co-authors study which brain cell types drive the protective effects of lowering mTOR signaling in Alzheimer's disease. The drug rapamycin, which blocks this pathway, extends life in many models and may protect the brain. It is unclear whether the benefit comes from lower inflammation, better cell cleanup, or both.
The team bred Alzheimer's model mice with greatly reduced mTOR, then restored normal levels in one cell type at a time: neurons, microglia, or astrocytes. Early results at one year show the expected rise in frailty from the disease and lower frailty when mTOR is reduced. Work in the cell-specific lines is ongoing to pinpoint where the protection acts.
Catalog record
| CREATOR | Kathryn A Haynes, Diogo Francisco Silva Santos, Sean‐Paul Gerard Williams, Jason T Hart, Alicia M Lehman, Seana E Eckels, Umesh Nepali, Aman Reddy, Toren Finkel, Stacey J Sukoff Rizzo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |